P768: GUADECITABINE (SGI-110) VS. TREATMENT CHOICE (TC) IN RELAPSED/REFRACTORY(R/R) MYELODYSPLASTIC SYNDROME (MDS), RESULTS OF A GLOBAL, RANDOMIZED, PHASE 3 STUDY.

P768: GUADECITABINE (SGI-110) VS. TREATMENT CHOICE (TC) IN RELAPSED/REFRACTORY(R/R) MYELODYSPLASTIC SYNDROME (MDS), RESULTS OF A GLOBAL, RANDOMIZED, PHASE 3 STUDY.

Bibliographic Details
Main Authors:	G. Garcia-Manero, S. Bart, J. K. McCloskey, P. Fenaux, D. Selleslag, G. Reda, D. Valcárcel, V. Santini, J. Mayer, B. Xicoy, H. Yamaguchi, M. Lübbert, Y. Miyazaki, H. Keer, Y. Hao, M. Azab, H. Döhner
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000845956.26644.d0

Similar Items

Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors
by: Robert Brown, et al.
Published: (2022-06-01)

The Secondary Myelodysplastic Neoplasms (MDS) Jigsaw
by: Oriol Calvete, et al.
Published: (2023-02-01)

P743: THE PIVOTAL ROLE OF GLUTAMINOLYSIS IN MYELODYSPLASTIC SYNDROME (MDS): A NOVEL STRATEGY FOR THE TARGETED THERAPY OF MDS
by: S. Okabe, et al.
Published: (2022-06-01)

MDS-197: Magrolimab + azacitidine versus azacitidine + placebo in untreated higher-risk (HR) myelodysplastic syndromes (MDS): the phase 3, randomized, ENHANCE study
by: Garcia-Manero, G, et al.
Published: (2021)

Trisomy X and myelodysplastic syndrome (MDS) with eosinophilia
by: Mohd Tohit, Eusni Rahayu, et al.
Published: (2012)

Assessing the Prognosis of Patients with Myelodysplastic Syndromes (MDS)
by: Annika Kasprzak, et al.
Published: (2022-04-01)

The role of azacitidine in the management of myelodysplastic syndromes (MDS)
by: KS G&ouml;tze, et al.
Published: (2009-10-01)

P765: UPDATED ENROLLMENT AND RESULTS FROM THE PHASE 1 SUBSTUDY OF IVOSIDENIB IN PATIENTS WITH IDH1-MUTANT RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROME (R/R MDS)
by: C. D. DiNardo, et al.
Published: (2022-06-01)

Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): a state-of-the-art report on behalf of the International Consortium for MDS (icMDS)
by: Stahl, M, et al.
Published: (2023)

Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS)
by: Josephine Lucero, et al.
Published: (2023-06-01)

Curcumin as an Epigenetic Therapeutic Agent in Myelodysplastic Syndromes (MDS)
by: Xiaoqing Xie, et al.
Published: (2021-12-01)

Cytogenetic study of Brazilian patients with myelodysplastic syndrome (MDS)
by: Tamara Borgonovo, et al.
Published: (2005-12-01)

Adults Myelodysplastic Syndromes in Algeria: A Study by the Algerian MDS Group
by: Mohamed Amine Bekadja, et al.
Published: (2023-04-01)

P719: RANDOMIZED PHASE 1-2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS: INTERIM SAFETY ANALYSIS
by: Guillermo Garcia-Manero, et al.
Published: (2023-08-01)

Toward a more patient‐centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)
by: Efficace, F, et al.
Published: (2024)

P778: LONG-TERM UTILIZATION AND BENEFIT OF LUSPATERCEPT IN PATIENTS (PTS) WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) FROM THE MEDALIST TRIAL
by: P. Fenaux, et al.
Published: (2022-06-01)

EHA Endorsement of the European Guidelines for Myelodysplastic Syndromes, MDS-RIGHT
by: Sabine Blum, et al.
Published: (2021-09-01)

Molecular Drivers of Myelodysplastic Neoplasms (MDS)—Classification and Prognostic Relevance
by: Fieke W. Hoff, et al.
Published: (2023-02-01)

THERAPY-RELATED MYELODYSPLASTIC SYNDROMES (t-MDS) IN CHILDHOOD: THE EXPERIENCE OF THE HELLENIC STUDY GROUP FOR MDS/JMML/SAA, MEMBER OF THE EWOG-MDS/SAA WORKING GROUP
by: Loizos Petrikkos, et al.
Published: (2023-12-01)

Qualitative flow cytometric analysis of Malaysian myelodysplastic syndromes (MDS) patients.
by: Broojerdi, Mohadese Hashem, et al.
Published: (2012)

Current State and Challenges in Development of Targeted Therapies in Myelodysplastic Syndromes (MDS)
by: Michele Stanchina, et al.
Published: (2021-04-01)

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk (HR) myelodysplastic syndromes (MDS): the Phase 3, randomized, ENHANCE Study
by: Garcia-Manero, G, et al.
Published: (2021)

Improving patient understanding and outcomes in myelodysplastic syndromes - An animated patient guide to MDS with visual formats of learning
by: David A. Sallman, et al.
Published: (2022-01-01)

Molecular mechanisms of Guadecitabine induced FGFR4 down regulation in alveolar rhabdomyosarcomas
by: Emad Darvishi, et al.
Published: (2020-07-01)

MDS-445 Magrolimab in combination with azacitidine for patients with untreated higher-risk myelodysplastic syndromes (HR MDS): 5F9005 phase 1b study results
by: Sallman, D, et al.
Published: (2022)

The Role of Hepcidin in Myelodysplastic Syndromes (MDS): A Systematic Review of Observational Studies
by: Artur Słomka, et al.
Published: (2024-01-01)

GFI1(36N) as a therapeutic and prognostic marker for myelodysplastic syndrome (MDS)
by: Botezatu, L, et al.
Published: (2016)

PB2021: PHASE 2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH MAGROLIMAB FOR PREVIOUSLY UNTREATED SUBJECTS WITH INTERMEDIATE TO VERY HIGH-RISK MYELODYSPLASTIC SYNDROMES (MDS)
by: Amer M. Zeidan, et al.
Published: (2023-08-01)

MDS-482 Impact of magrolimab in combination with azacitidine on red blood cells (RBCs) in patients with higher-risk myelodysplastic syndromes (HR MDS)
by: Chen, J, et al.
Published: (2022)

EFFICACY AND SAFETY OF LUSPATERCEPT VERSUS EPOETIN ALFA IN ERYTHROPOIESIS-STIMULATING AGENT (ESA)-NAIVE PATIENTS WITH TRANSFUSION-DEPENDENT LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS): FULL ANALYSIS OF THE COMMANDS TRIAL
by: G. Garcia-Manero, et al.
Published: (2024-01-01)

Validation of International Working Group response criteria in higher‐risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium
by: Rami S. Komrokji, et al.
Published: (2021-01-01)

S170: MYELODYSPLASTIC NEOPLASMS (MDS) CLASSIFICATION FROM WHO 2017 TO WHO 2022 AND ICC 2022): AN EXPANDED ANALYSIS OF 7017 PATIENTS ON BEHALF OF THE INTERNATIONAL CONSORTIUM FOR MDS (ICMDS)
by: Rami S. Komrokji, et al.
Published: (2023-08-01)

On Thermal Expansion and Density of CGI and SGI Cast Irons
by: Taishi Matsushita, et al.
Published: (2015-06-01)

DHPLC analysis of the ATRX gene in myelodysplastic syndrome (MDS) associated with acquired alpha thalassemia (AT-MDS): Novel mutation detection despite somatic mosaicism.
by: Steensma, D, et al.
Published: (2003)

P788: FACTORS DRIVING TREATMENT DECISION IN PATIENTS WITH INTERMEDIATE-RISK MYELODYSPLASTIC SYNDROME (MDS): A RETROSPECTIVE ANALYSIS FROM THE GRUPO ESPAÑOL DE SÍNDROMES MIELODISPLÁSICOS SPANISH MDS REGISTRY
by: M. Díez-Campelo, et al.
Published: (2022-06-01)

P108: Myelodysplastic syndrome (MDS) detected by germline genetic testing for hereditary cancer
by: Larissa Peck, et al.
Published: (2024-01-01)

Infectious Complications in Patients with Myelodysplastic Syndromes: A Report from the Düsseldorf MDS Registry
by: Annika Kasprzak, et al.
Published: (2024-02-01)

The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype?
by: Anson Snow, et al.
Published: (2022-07-01)

Therapy related myelodysplastic syndrome (t-MDS) in childhood Acute lymphoblastic leukemia- an interesting observation
by: Kavita Gaur, et al.
Published: (2022-01-01)

Cost-effectiveness of azacitidine compared with low-doses of chemotherapy (LDC) in myelodysplastic syndrome (MDS)
by: Myrna Candelaria-Hernández, et al.
Published: (2017-06-01)